In keeping with the hypothesis that LAG‐3 may limit clinical responses to currently approved immune checkpoint inhibitors, co‐expression of LAG‐3 and PD‐1 was reported on both CD4+ and CD8+ TIL isolated from primary tumors of renal cell carcinoma patients, and when compared to PD‐1 blockade alone, dual blockade of both LAG‐3 and PD‐1 enhanced IFN‐γ production by these cells following ex vivo stimulation.165. Here, LAG3 is linked to renal cell carcinoma.